Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055279 | 0.88 | PTGDR2 (0.43) | PTGDR2AKR1B1CYP2C9LIPELMNA | |
| SCHEMBL1055280 | 0.88 | PTGDR2 (0.43) | PTGDR2AKR1B1CYP2C9LIPELMNA | |
| SCHEMBL1053305 | 0.80 | PTGDR2 (0.55) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL11891657 | 0.76 | KDM4E (0.42) | PTGDR2AKR1B1CYP2C9LIPEKDM4E | |
| SCHEMBL1053997 | 0.68 | PTGDR2 (0.67) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1054190 | 0.68 | PTGDR2 (0.56) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1050250 | 0.67 | SMN1; SMN2 (0.45) | PTGDR2CYP2C9KDM4ESMN1; SMN2LMNA | |
| SCHEMBL11891664 | 0.67 | PTGDR2 (0.52) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1054690 | 0.67 | PTGDR2 (0.52) | PTGDR2AKR1B1CYP2C9 | |
| SCHEMBL1054693 | 0.67 | PTGDR2 (0.52) | PTGDR2AKR1B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | ASTRAZENECA AB (SE) | 2011-02-24 | — | — | US | disclosed |
| WO-2011004182-A1 | INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF 4- (ACETYLAMINO) ) -3- [ (4-CHLORO-PHENYL) THIO] -2-METHYL-1H-INDOLE-1-ACETIC ACID | ASTRAZENECA AB (SE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046394-A1 | Pharmaceutical Process and Intermediates 714 | CYP3A4, CYP4A11, CYP4B1 | PTGDR2 3430/4885AKR1B1 298/4885CYP2C9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.